Karyopharm Therapeutics IncKPTI
Price$0.87

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $151.1M+17.0% YoYTTM through 31 Mar 2026
Net Income -$195MTTM through 31 Mar 2026
Free Cash Flow -$59.1MTTM through 31 Mar 2026

Margins

Current
Gross Margin96.2%
Operating Margin-76.2%
Net Margin-63.8%

Returns

8.4%ROE
-17.0%ROA

Balance Sheet Health

Debt / Equity-0.85x
Current Ratio2.58x
Net Debt$133.7M
Cash & Equivalents$90.9M

Quality Metrics

FCF Margin-39.1%
Earnings-Beat Rate25.0%

Dividend

No dividend
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.